{"Clinical Trial ID": "NCT02748213", "Intervention": ["INTERVENTION 1:", "Herceptin + Taxotere + Xeloda", "The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was administered between Cycle 2 and the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was administered orally at 950 mg/m^2 twice daily on days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity.", "INTERVENTION 2:", "- Herceptin + Taxotere", "The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 to the end of treatment. The dose of Taxotere was 100 mg/m^2, with only toxicity adjustments."], "Eligibility": ["Incorporation criteria:", "In histologically confirmed, advanced and/or metastatic HER2-positive breast cancer is not suitable for curative treatment", "At least one measurable injury according to RECIST", "The Eastern Cooperative Oncology Group (ECOG) achieved a yield of 0 or 1", "At the base, left ventricular ejection fraction (VEF) at least 50%", "- Exclusion criteria:", "\u2022 Pregnant, lactating or childbearing women who are not surgically sterile or who are not willing to use adequate contraceptive methods", "Previous treatment with Herceptin or other anti-HER treatments, or any previous chemotherapy for advanced or metastatic disease", "\u2022 Significant previous medical history for any central nervous system or cardiac disorder (CNS)", "Low haematological, renal or hepatic function", "Treatment of chronic corticosteroids"], "Results": ["Performance measures:", "Percentage of participants with the best overall response of the complete (RC) or partial (PR) response according to the solid tumour response assessment criteria (RCIST)", "The response of tumours was evaluated by RECIST during the study. RC was defined as the elimination of all target and non-target lesions and the normalization of tumour marker levels. PR was defined as greater than or equal to ( ) 30 percent (%) decrease in the sum of longer diameter (LD) of the target lesions from the base sum LD. The response was confirmed 4 weeks after the initial assessment of CR or PR. The percentage of participants with the best overall response for CR or PR was reported. The exact 95% confidence interval (CI) for a binomial sample was determined using the Pearson-Clopper method.", "Time frame: Assessment of tumours at baseline, then every 6 weeks to cycle 8 (duration of 21-day cycle), then every 12 weeks to progressive disease and/or one year after enrolment; thereafter, according to current clinical practice (up to 66 months in total)", "Results 1:", "Title of the arm/group: Herceptin + Taxotere + Xeloda", "The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1 and a maintenance dose of 6 mg/kg was administered from Cycle 2 to the end of treatment. The dose of Taxotere was 75 mg/m^2, with adjustments allowed only for toxicity. Xeloda was administered orally at 950 mg/m^2 twice daily on days 1 to 14 of each 21-day cycle, with adjustments allowed only for toxicity. Xeloda was administered orally at 950 mg/m^2 twice daily on days 1 to 14 of each 21-day cycle.", "Total number of participants analysed: 112", "Type of measurement: Number", "Unit of measure: percentage of participants 70.5 (61.18 to 78.77)", "Results 2:", "Title of the arm/group: Herceptin + Taxotere", "The first dose of Herceptin was a loading dose of 8 mg/kg in Cycle 1, and a maintenance dose of 6 mg/kg was given from Cycle 2 to the end of treatment. The dose of Taxotere was 100 mg/m^2, with adjustments allowed only for toxicity.", "Total number of participants analysed: 110", "Type of measurement: Number", "Unit of measure: percentage of participants 72.7 (63.41 to 80.78)"], "Adverse Events": ["Undesirable Events 1:", "Total: 52/112 (46.43 per cent)", "Febrile neutropenia * 16/112 (14.29%)", "Neutropenia * 7/112 (6.25 per cent)", "Anemia * 1/112 (0.89%)", "* 1/112 (0.89%)", "Coronary artery disorders * 1/112 (0.89%)", "Left ventricular dysfunction * 1/112 (0.89%)", "Pericardial infusion * 0/112 (0.00 %)", "Hyperthyroidism * 1/112 (0.89%)", "Diarrhoea * 5/112 (4.46%)", "Vomiting * 3/112 (2.68 per cent)", "Adverse Events 2:", "Total: 51/110 (46.36 per cent)", "Febrile neutropenia * 26/110 (23.64 %)", "Neutropenia * 7/110 (6.36%)", "Anemia * 1/110 (0.91%)", "Heart failure * 0/110 (0.00 %)", "Coronary heart disease * 0/110 (0.00 %)", "Left ventricular dysfunction * 0/110 (0.00 %)", "* 1/110 (0.91%)", "Hyperthyroidism * 0/110 (0.00 %)", "Diarrhoea * 0/110 (0.00 %)", "Vomiting * 1/110 (0.91%)"]}